Cipla vs Sunpharma Q3 FY26

Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY). PAT of INR 676 crore included a one-time INR 276 crore labor code charge. U.S. revenue fell to $167 million as Lenalidomide tapered and lanreotide supply was disrupted (partner Pharmathen paused production after FDA observations; resupply expected H1 FY27). India business grew 10% YoY, with respiratory crossing INR 5,000 crore. FY26 EBITDA margin guidance revised to ~21%. Key upcoming U.S. launches (4 respiratory, 4 peptide assets) are expected to offset revenue declines, but near-term headwinds persist. Risk: lanreotide disruption may extend beyond H1 FY27 if remediation is delayed.

Guidance read

FY26 EBITDA margin guidance revised to ~21%: Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact. U.S. launches: 4 respiratory and 4 peptide assets in FY27: Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza. Lanreotide resupply expected in H1 FY27: Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway. FY27 guidance to be provided next quarter: Management will provide FY27 guidance after finalizing the annual operating plan.

Risk read

Key risks include Lanreotide supply disruption may extend beyond H1 FY27 — Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.; U.S. launch pipeline may face delays or competition — Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.; Elevated R&D spend may persist, pressuring margins — R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.; Semaglutide generic launch could impact tirzepatide uptake — Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales. EBITDA margin expanded to 31.9% on better product mix, while PAT grew 16% to INR 3,369 crore despite a higher tax rate. Management highlighted the upcoming launch of generic semaglutide in India as a key growth catalyst, with approvals received for both diabetes and weight management. However, US generic sales remain under pressure from competition and manufacturing compliance issues, and the company faces uncertainty from proposed US pricing reforms. The strong balance sheet (net cash $3.2B) provides M&A flexibility, though management remains disciplined.

Guidance read

Semaglutide launch in India on patent expiry: Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity. R&D spend guidance for next year: Management indicated they will provide R&D spend guidance for the next fiscal year in the next quarter's call. Phase 2b trial for GL0034 to complete in 12-18 months: The phase 2b study for GL0034 in type 2 diabetes has started and is expected to complete within 12-18 months.

Risk read

Key risks include US generic sales pressure from competition — US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.; Proposed US Most Favored Nation pricing models — CMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.; Higher effective tax rate impacting PAT growth — Effective tax rate rose to ~25% from ~15% last year, dampening PAT growth relative to EBITDA growth; expected to remain in that range.; Milestone income may not recur — Management noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability..

Promise ledger

Of 3 tracked promises, management 0 met, 0 close, 3 missed.